Gene Editing Technologies Market by Offering, Technology, Application, End User

Description

List of Tables

[181 Pages Report] The Gene Editing Technologies Market size was estimated at USD 5.12 billion in 2023 and expected to reach USD 5.73 billion in 2024, at a CAGR 12.57% to reach USD 11.74 billion by 2030.

Global Gene Editing Technologies Market

KEY MARKET STATISTICS
Base Year [2023]	USD 5.12 billion
Estimated Year [2024]	USD 5.73 billion
Forecast Year [2030]	USD 11.74 billion
CAGR (%)	12.57%

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Gene Editing Technologies Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Gene Editing Technologies Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Gene Editing Technologies Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., AMS Biotechnology Ltd., Beam Therapeutics Inc., Caribou Biosciences, Inc., Cellectis SA, Creative Biogene, CRISPR Therapeutics AG, Editas Medicine, Inc., GenScript Biotech Corporation, Horizon Discovery Ltd., Inscripta, Inc., Integrated DNA Technologies, Inc., Intellia Therapeutics, Inc., Lonza Group Ltd., Mammoth Biosciences, Inc., Merck Group, New England Biolabs, Inc., OriGene Technologies, Inc., Precision BioSciences, Inc., Sangamo Therapeutics, Inc., Synthego Corporation, Takara Bio Inc., Tecan Trading AG, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Gene Editing Technologies Market to forecast the revenues and analyze trends in each of the following sub-markets:

Offering
- Reagents & Consumables
- Services
- Software & Systems
Technology
- Antisense
- CRISPR
- Talen
- Zinc Finger Nucleases (ZFN)
Application
- Animal Genetic Engineering
- Cell Line Engineering
- Genetic Engineering
- Plant Genetic Engineering
End User
- Academic & Government Research Institutes
- Biotechnology & Pharmaceutical Companies
- Contract Research Organizations
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Gene Editing Technologies Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Gene Editing Technologies Market?

3. What are the technology trends and regulatory frameworks in the Gene Editing Technologies Market?

4. What is the market share of the leading vendors in the Gene Editing Technologies Market?

5. Which modes and strategic moves are suitable for entering the Gene Editing Technologies Market?

Product Code: MRR-2E76C3E47FDD

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Gene Editing Technologies Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of genetic disorders worldwide
  - 5.1.1.2. Increasing investments for R&D in gene editing
  - 5.1.1.3. Significant improvements in CRISPR-based tools
- 5.1.2. Restraints
  - 5.1.2.1. High cost of development of gene editing technologies
- 5.1.3. Opportunities
  - 5.1.3.1. Technological advancements in gene editing technologies
  - 5.1.3.2. Inclination toward personalized medicine approach
- 5.1.4. Challenges
  - 5.1.4.1. Ethical concerns and stringent regulatory framework
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Gene Editing Technologies Market, by Offering

6.1. Introduction
6.2. Reagents & Consumables
6.3. Services
6.4. Software & Systems

7. Gene Editing Technologies Market, by Technology

7.1. Introduction
7.2. Antisense
7.3. CRISPR
7.4. Talen
7.5. Zinc Finger Nucleases (ZFN)

8. Gene Editing Technologies Market, by Application

8.1. Introduction
8.2. Animal Genetic Engineering
8.3. Cell Line Engineering
8.4. Genetic Engineering
8.5. Plant Genetic Engineering

9. Gene Editing Technologies Market, by End User

9.1. Introduction
9.2. Academic & Government Research Institutes
9.3. Biotechnology & Pharmaceutical Companies
9.4. Contract Research Organizations

10. Americas Gene Editing Technologies Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Gene Editing Technologies Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Gene Editing Technologies Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. Agilent Technologies, Inc.
- 14.1.2. AMS Biotechnology Ltd.
- 14.1.3. Beam Therapeutics Inc.
- 14.1.4. Caribou Biosciences, Inc.
- 14.1.5. Cellectis SA
- 14.1.6. Creative Biogene
- 14.1.7. CRISPR Therapeutics AG
- 14.1.8. Editas Medicine, Inc.
- 14.1.9. GenScript Biotech Corporation
- 14.1.10. Horizon Discovery Ltd.
- 14.1.11. Inscripta, Inc.
- 14.1.12. Integrated DNA Technologies, Inc.
- 14.1.13. Intellia Therapeutics, Inc.
- 14.1.14. Lonza Group Ltd.
- 14.1.15. Mammoth Biosciences, Inc.
- 14.1.16. Merck Group
- 14.1.17. New England Biolabs, Inc.
- 14.1.18. OriGene Technologies, Inc.
- 14.1.19. Precision BioSciences, Inc.
- 14.1.20. Sangamo Therapeutics, Inc.
- 14.1.21. Synthego Corporation
- 14.1.22. Takara Bio Inc.
- 14.1.23. Tecan Trading AG
- 14.1.24. Thermo Fisher Scientific, Inc.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing